non-small cell lung cancer

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Thu, 10/29/20 - 12:17 pm
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
Triple meeting – the point of turning to TPX-0022
EP Vantage
Tue, 10/27/20 - 10:32 am
Turning Point Therapeutics
repotrectinib
TPX-0022
non-small cell lung cancer
Merck touts new data for Keytruda combos in NSCLC at North American conference
Endpoints
Mon, 10/19/20 - 10:47 am
Merck
clinical trials
Keytruda
non-small cell lung cancer
IASLC
Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo
BioSpace
Wed, 10/7/20 - 11:41 pm
Bristol-Myers Squibb
clinical trials
non-small cell lung cancer
Opdivo
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Fierce Biotech
Tue, 10/6/20 - 10:26 am
Amgen
clinical trials
non-small cell lung cancer
KRAS
sotorasib
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
BioSpace
Tue, 09/22/20 - 11:10 am
AstraZeneca
clinical trials
Tagrisso
ESMO
non-small cell lung cancer
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Mon, 09/21/20 - 10:57 am
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Amgen publishes, presents data on therapy with ‘undruggable’ target
MedCity News
Mon, 09/21/20 - 10:33 am
Amgen
sotorasib
ESMO
AMG 510
non-small cell lung cancer
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
Sat, 09/19/20 - 09:05 pm
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Sun, 09/6/20 - 07:22 pm
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?
Endpoints
Wed, 08/19/20 - 12:18 pm
Turning Point Therapeutics
repotrectinib
non-small cell lung cancer
clinical trials
Pfizer
Roche
Deaths from the most common lung cancer are falling fast, hinting at the impact of improved treatment
Stat
Wed, 08/12/20 - 11:51 pm
lung cancer
non-small cell lung cancer
targeted therapeutics
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Sun, 08/9/20 - 11:14 pm
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Pharmaceutical Business Review
Fri, 08/7/20 - 11:10 am
Daiichi Sankyo
AstraZeneca
patritumab deruxtecan
Tagrisso
non-small cell lung cancer
clinical trials
Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program
Endpoints
Tue, 07/21/20 - 10:58 am
Elevation Oncology
Merrimack
seribantumab
non-small cell lung cancer
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
BioSpace
Wed, 07/15/20 - 11:16 pm
Merck
Novocure
clinical trials
tumor treating fields
Keytruda
non-small cell lung cancer
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
BioSpace
Tue, 06/23/20 - 11:39 pm
Daiichi Sankyo
Thermo Fisher
companion diagnostics
diagnostics
non-small cell lung cancer
NICE backs funding for Roche’s lung cancer drug after price cut
Pharmaforum
Mon, 06/15/20 - 10:21 am
NICE
Roche
Rozlytrek
non-small cell lung cancer
Marketing Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod
Fierce Pharma
Mon, 06/1/20 - 11:34 pm
Eli Lilly
Cyramza
FDA
non-small cell lung cancer
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020

Pages